Form 8-K - Current report:
SEC Accession No. 0001827506-25-000025
Filing Date
2025-03-13
Accepted
2025-03-13 08:00:44
Documents
15
Period of Report
2025-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trml-20250313.htm   iXBRL 8-K 28282
2 EX-99.1 a03132025exhibit991.htm EX-99.1 63777
6 tourmalinelogoa.jpg GRAPHIC 83884
  Complete submission text file 0001827506-25-000025.txt   348295

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trml-20250313.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trml-20250313_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trml-20250313_pre.xml EX-101.PRE 13593
17 EXTRACTED XBRL INSTANCE DOCUMENT trml-20250313_htm.xml XML 2915
Mailing Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010
Business Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010 646-481-9832
Tourmaline Bio, Inc. (Filer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 25733869
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)